Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corporation reports developments as a medical technology company focused on minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease. Its commercial platform includes the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform and StratX Lung Analysis Reports, which are designed to assess and treat symptomatic severe emphysema/COPD patients. The Zephyr Valve received FDA premarket approval after breakthrough device designation and is commercially available in more than 25 countries.
Recurring Pulmonx news covers quarterly and annual financial results, U.S. and international revenue trends, gross margin, commercial execution, clinical program activity, debt refinancing, cost initiatives, inducement equity awards and governance or leadership changes.
Pulmonx (Nasdaq:LUNG) reported second quarter 2026 revenue of $22.8 million, down 5% year over year, or 6% on a constant currency basis. U.S. revenue was $14.2 million (-4% YoY) and international revenue was $8.6 million (-6% YoY, -9% constant currency). According to Pulmonx, international revenue excluding China grew 12% year over year (9% constant currency) as China sales paused pending renewal of a registration certificate.
Gross profit was $17.7 million with a record 78% gross margin, up from 72% a year earlier. Operating expenses declined 16% to $26.8 million. Net loss improved to $10.1 million (or $0.24 per share) from $15.2 million, and adjusted EBITDA loss narrowed to $5.1 million from $8.4 million. Cash and cash equivalents were $55.8 million on June 30, 2026. Pulmonx reaffirmed 2026 revenue guidance of $90–$92 million, now expects full-year gross margin of about 76%, operating expenses of $109–$111 million, and projects a $23 million reduction in cash, cash equivalents, and marketable securities for 2026.
Pulmonx (Nasdaq: LUNG) will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET. A live and archived webcast will be accessible via the Investors section of the Pulmonx website.
Pulmonx (Nasdaq: LUNG) will release its second quarter 2026 financial results after market close on Wednesday, July 29, 2026. Company management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, with live and archived webcast access via the Investors section of the Pulmonx website.
Pulmonx (Nasdaq:LUNG) granted equity awards under its 2025 Inducement Plan to 17 new employees hired in the first two quarters of 2026. According to Pulmonx, these Nasdaq Listing Rule 5635(c)(4) inducement awards total 84,300 RSUs with four-year vesting starting on June 1, 2026.
Pulmonx (Nasdaq: LUNG) reported Q1 2026 results: revenue $20.6M (down 9% YoY; -12% constant currency), with U.S. $13.3M and international $7.3M (China-related decline; ex-China international +22% YoY). Gross margin was 78%, net loss $13.7M (EPS -$0.33), cash $61.6M. Full-year 2026 guidance: revenue $90M–$92M, gross margin ~75%, operating expenses $113M–$115M. Company refinanced debt with a 5-year interest-only facility extending maturity to 2031.
Pulmonx (Nasdaq: LUNG) will present at the Bank of America Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026 at 8:15 AM PT / 11:15 AM ET. A live and archived webcast will be available in the Investors section of the company website.
Pulmonx (Nasdaq: LUNG) will report first quarter 2026 financial results after the close of trading on Wednesday, April 29, 2026.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, with a live and archived webcast available in the Investors section of the Pulmonx website.
Pulmonx (Nasdaq: LUNG) reported fourth quarter and full year 2025 results on March 4, 2026. Total 2025 revenue was $90.5M, up 8% year-over-year; Q4 revenue was $22.6M, down 5% year-over-year. Gross margin was 78% in Q4 and 74% for 2025. The company refinanced debt, securing up to $60M under a new five-year interest-only credit facility and implemented cost restructuring. Cash and marketable securities were $69.8M at year-end, down about $32M year-over-year. 2026 guidance calls for revenue of $90M–$92M, ~75% gross margin, and operating expenses of $113M–$115M.
Pulmonx (Nasdaq: LUNG) closed a five-year credit facility with Perceptive Advisors for up to $60 million on March 4, 2026. The facility funds a $40 million term loan drawn at closing to refinance existing debt and a conditional $20 million undrawn option through end of 2027.
The loan is interest-only until its 2031 maturity, bears interest at one-month Term SOFR (3.75% floor) plus 7.0%, and allows 2.0% paid-in-kind interest at the company’s option for three years.
Pulmonx (Nasdaq: LUNG) will report its fourth quarter and full year 2025 financial results after market close on Wednesday, March 4, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET and a live archived webcast will be available on the company investor website.